Skip to content

Treatment with Teasing Needle on Low Back Myofascitis: A Single-center, Open-label, randomized Controlled Clinical Trial

Clinical effectiveness and safety of Teasing needle release in the treatment of chronic low back myofascial pain syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124374
Enrollment
Unknown
Registered
2026-05-11
Start date
2024-07-30
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Back Myofascitis

Interventions

TN Group:Ultrasound-guided Teasing needle fasciotomy for fascia release + standardized postoperative rehabilitation exercises
Control Group:Celecoxib oral medication treatment (0.2g once daily, continuous administration for 1 month)

Sponsors

Shanghai East Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Over 18 years of age; 2. Persistent chronic low back pain for at least 3 months and met the clinical diagnostic criteria of MPS; 3. Failure of conservative treatment (physical therapy, drug therapy, etc.) 4. Patients voluntarily signed informed consent and were able to complete the questionnaire.

Exclusion criteria

Exclusion criteria: 1. Patients aged under 18 years; 2. Patients with a history of thoracolumbar trauma, or those having undergone thoracolumbar surgery within 3 months prior to enrollment; 3. Patients whose low back pain was confirmed by imaging and clinical examinations to be secondary to other pathologies, including but not limited to thoracolumbar deformity, cervical spondylosis, cardiovascular diseases, mediastinal lesions, thoracic tuberculosis or neoplasms, intraspinal lesions, and abdominal visceral disorders; 4. Pregnant or lactating women, patients with psychiatric disorders, or those with failure of vital organs including the heart, liver, kidney, and hematopoietic system; 5. Patients with contraindications to teasing needle therapy, such as coagulation dysfunction and infection at the puncture site; 6. Patients with known hypersensitivity to study-related medications, including lidocaine, celecoxib, and other non-steroidal anti-inflammatory drugs (NSAIDs); 7. Patients with poor treatment compliance, inability to complete the treatment and follow-up as required by the study protocol, or a high risk of dropout or loss to follow-up during the study.

Design outcomes

Primary

MeasureTime frame
Numeric Rating Scale;

Secondary

MeasureTime frame
Oswestry Disability Index;Pittsburgh Sleep Quality Index;36-Item Short-Form Health Survey;Clinical treatment effectiveness rate;

Countries

China

Contacts

Public ContactLijun Liao

Shanghai East Hospital, School of Medicine, Tongji University

18340807363@163.com+86 138 1742 8913

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026